Ipilimumab N01 clinical trials
How each study uses ipilimumab N01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ipilimumab N01 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 5
Fudan University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Sun Yat-sen University (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ipilimumab N01.
- Apr 2027Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaPhase 2 · Tianjin Medical University Cancer Institute and Hospital
Studies
Open first, then newest update. How each study uses ipilimumab N01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskRecruitingPhase 2Sun Yat-sen UniversityNCT07487662Written as ipilimumab N01
- First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingPhase 2Fudan UniversityNCT07893340Written as Ipilimumab N01
- A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction CancerNot yet recruitingPhase 2Fudan UniversityNCT07878221Written as Ipilimumab N01
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2/3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT07643623Written as Ipilimumab N01
- Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07560488Written as ipilimumab N01
- A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07506109Written as Ipilimumab N01
What changed recently
From the registry's own updates since Oct 20, 2026.